|
WO2018081083A1
|
|
Phospholipid-cholesteryl ester nanoformulations and related methods
|
|
WO2018045346A1
|
|
Methods for treating cancer and determining efficacy of treatment
|
|
WO2018031577A1
|
|
Fixed dose combination for pain relief without edema
|
|
WO2018009895A1
|
|
Methods for trabedersen dosing by auc
|
|
WO2018009842A1
|
|
Methods for rosuvastatin dosing by auc
|
|
WO2017218630A2
|
|
Phospholipid-coated therapeutic agent nanoparticles and related methods
|
|
WO2017210626A1
|
|
Antibody-functionalized carbon nanotube-based field effect transistors and their use for immunoassay of paclitaxel
|
|
TW201809655A
|
|
Prussian blue screen-printed electrode for determining cation concentration in physiological samples
|
|
WO2017190028A1
|
|
Methods for treating cancers using ace inhibitors, arb, or celecoxib and olmesartan
|
|
US2017326109A1
|
|
Fixed Dose Combination for Pain Relief Without Edema
|
|
WO2017124078A1
|
|
Celcoxib binding antibodies and uses thereof
|
|
US2017199208A1
|
|
Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
|
|
WO2017062830A1
|
|
Antibody-based affinity reagents for binding paclitaxel
|
|
WO2017024312A1
|
|
Phospholipid-cholesteryl ester nanoformulations and related methods
|
|
US2016346219A1
|
|
Phospholipid-coated therapeutic agent nanoparticles and related methods
|
|
WO2016196648A1
|
|
Phospholipid-coated therapeutic agent nanoparticles and related methods
|
|
WO2017138924A1
|
|
Compositions and methods for treating pancreatic cancer
|
|
US2017226518A1
|
|
Compositions and methods for treating cancer
|
|
US2017226517A1
|
|
Compositions and methods for treating pancreatic cancer
|
|
KR20180103817A
|
|
Compositions and methods for treating cancer
|
